Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy - Cancer Cell International

  • 📰 BioMedCentral
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 71%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

A Review published in Cancer Cell International examines the potential use of nanobodies that are naturally secreted in camels’ biological fluids in the development of nanotechnology-based therapy for treating different types of cancers.

]. The animal with ARDS treated with camel milk displayed a notable reduction in the pulmonary wet: dry weight ratio, neutrophil infiltration, alveolar and interstitial edema, lung damage, and improvement in pulmonary functions. Additionally, camel milk administration alleviated the pulmonary recruitment of numerous cytokines and oxidative stress factors. Interestingly, the observed camel milk therapeutic effects were postulated to happen through suppression of the MAPK signalling cascade [].

In vivo Administration of camel milk for 3 weeks reduced dramatically the levels of the biomarkers related to renal damage such as serum creatinine, BUN, and KIM-1. Furthermore, camel milk treatment is associated with a marked lowering in numerous inflammatory cytokines and degradation signals such as MCP-1, IL-8, TNF, MMP-2, and MMP-9.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 22. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Researchers discover new tool for improving pancreatic cancer careThe statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030. Surgery remains the most effective treatment, yet for 70-80% of patients, surgery is not a viable option. Understanding pancreatic cancer at the cellular and subcellular level is essential for developing therapies that can buy patients more time.
Source: medical_xpress - 🏆 101. / 51 Read more »

Apple co-founder Steve Jobs memorialized with online archiveApple co-founder Steve Jobs memorialized with online archive of emails, guff
Source: TheRegister - 🏆 67. / 61 Read more »

Sneak peek: FiveTen’s new Kestrel BOA shoe and Breast Cancer Awareness collectionFiveTen/Adidas snuck some new kicks into Crankworx Whistler, including the incoming Kestrel BOA and several Breast Cancer Awareness shoes.
Source: bikerumor - 🏆 65. / 61 Read more »

Accumulation of copy number alterations and clinical progression across advanced prostate cancer - Genome MedicineBackground Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication of copy number change in advanced prostate cancer, which defines a wide spectrum of disease from high-risk localised to metastatic, is unknown. Methods We performed copy number profiling on 688 tumour regions from 300 patients, who presented with advanced prostate cancer prior to the start of long-term androgen deprivation therapy (ADT), in the control arm of the prospective randomised STAMPEDE trial. Patients were categorised into metastatic states as follows; high-risk non-metastatic with or without local lymph node involvement, or metastatic low/high volume. We followed up patients for a median of 7 years. Univariable and multivariable Cox survival models were fitted to estimate the association between the burden of copy number alteration as a continuous variable and the hazard of death or disease progression. Results The burden of copy number alterations positively associated with radiologically evident distant metastases at diagnosis (P=0.00006) and showed a non-linear relationship with clinical outcome on univariable and multivariable analysis, characterised by a sharp increase in the relative risk of progression (P=0.003) and death (P=0.045) for each unit increase, stabilising into more modest increases with higher copy number burdens. This association between copy number burden and outcome was similar in each metastatic state. Copy number loss occurred significantly more frequently than gain at the lowest copy number burden quartile (q=4.1 × 10−6). Loss of segments in chromosome 5q21-22 and gains at 8q21-24, respectively including CHD1 and cMYC occurred more frequently in cases with higher copy number alteration (for either region: Kolmogorov–Smirnov distance, 0.5; adjusted P|0.0001). Copy number alterations showed variability across tumour regions in the same prostate. This variance associated with increased risk
Source: BioMedCentral - 🏆 22. / 71 Read more »

Royal physician, Professor Sir Huw Thomas, juggled cancer research while caring for The QueenRoyal physician, Professor Sir Huw Thomas, juggled cancer research while caring for The Queen ➡️ Sir Huw, who was called upon ‘as and when I’m needed’, described the Royal Family as ‘just like other patients’
Source: i newspaper - 🏆 8. / 89 Read more »